קורונהוויירוס אין א״י

אבינו מלכנו מנע מגיפה מנחלתך - אלעס ארום די קאראנא וויירוס

די אחראים: יאנאש,אחראי,געלעגער

אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

moishy56 האט געשריבן:מדינת ישראל האט שוין וואקסינירט 21.38 פראצענט
פון אלע אירע בירגער.

israel vax 11 jan.jpg

כשם שמספרי הנדבקים זייפו בגדול
כך גם מספרי המחוסנים מזוייף.
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
אוועטאר
moishy56
שר עשרת אלפים
תגובות: 19657
זיך איינגעשריבן אום: זונטאג נאוועמבער 10, 2013 6:36 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך moishy56 »

שיא מדאיג במספר הנדבקים היומי: קרוב ל-9,600 מאומתים ביממה

יום ג' וארא - כ"ח טבת תשפ"א.

9,589 חולי קורונה נוספים אובחנו בישראל במהלך היממה האחרונה,
בכך עולה מספר מספר החולים מתחילת ההתפרצות הנגיף בארץ ל-504,269, כך עולה מנתוני משרד הבריאות שפורסמו הבוקר (שלישי). על פי הנתונים, אמש בוצעו 92,967 בדיקות לחשודים כחולי קורונה.

מספר החולים הפעילים עומד נכון להבוקר על 74,639. מספר המונשמים ממשיך לעלות ועומד כעת על 247 חולים הזקוקים למכונת הנשמה מתוך 1,027 חולים במצב קשה המאושפזים בבתי החולים.
מספר הנפטרים עולה אף הוא ועומד כעת על 3,704.

שיעור התוצאות החיוביות מסך הבדיקות הכולל, עומד הבוקר על 7.6%.

הנתונים הגבוהים מגיעים על אף הסגר הכללי, שנכנס ליומו החמישי. נראה כי הסגר, וגם תקופת ההגבלות שקדמה לה, לא נותנים את אותותיהם, וכי המוטציה הבריטית, המדבקת בהרבה, ממשיכה להתפשט בישראל.

אתמול חצתה ישראל את רף חצי מיליון נדבקים מפרוץ מגפת הקורונה, והפכה למדינה ה-29 בעולם שבה אובחנו יותר מ-500 אלף נדבקים מאומתים בנגיף. בכירה במערך "מגן ישראל", שמוביל פרויקטור הקורונה פרופ' נחמן אש, הביעה אתמול "אופטימיות זהירה", כמה ימים לאחר כניסתו לתוקף של הסגר המהודק. ד"ר אורלי גרינפלד, המנהלת הרפואית ב"מגן ישראל", אמרה בתדרוך לעיתונאים כי "אנחנו רואים ירידה בתנועתיות ובמגעים" וכן "מיתון קל בקצב ההדבקה".
.

טעקסט בלויז די ווארט INFO צו 718-480-0545 און מען ארלעדיגט דיר א פאלעסי #קהלייף
אוועטאר
אוראייניקל
רב הצעיר תשפ"ד
תגובות: 16943
זיך איינגעשריבן אום: דאנערשטאג פעברואר 21, 2019 9:05 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך אוראייניקל »

שמואל בארג האט געשריבן:אין די סעריע פון עליגעיטערס:

נתניהו עדכן כי חבר הכנסת משה גפני לקה בהתקף לב ולאחר כמה דקות תיקן: קיבלתי דיווח פייק ניוז, הוא רק קיבל חיסון.

געמיינט סאיז א ווערטל, ס'איז אבער טאקע געשען.
https://drive.google.com/file/d/1tW5eSx ... sp=sharing
חוח בין השושנים האט געשריבן:
אוועטאר
אוראייניקל
רב הצעיר תשפ"ד
תגובות: 16943
זיך איינגעשריבן אום: דאנערשטאג פעברואר 21, 2019 9:05 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך אוראייניקל »

-תירוץ-חדש.jpg
-תירוץ-חדש.jpg (41.44 KiB) געזען 1999 מאל
חוח בין השושנים האט געשריבן:
אוועטאר
אוראייניקל
רב הצעיר תשפ"ד
תגובות: 16943
זיך איינגעשריבן אום: דאנערשטאג פעברואר 21, 2019 9:05 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך אוראייניקל »

-מוטציה-ורוטציה.JPG
-מוטציה-ורוטציה.JPG (22.32 KiB) געזען 1999 מאל
חוח בין השושנים האט געשריבן:
אוועטאר
אוראייניקל
רב הצעיר תשפ"ד
תגובות: 16943
זיך איינגעשריבן אום: דאנערשטאג פעברואר 21, 2019 9:05 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך אוראייניקל »

-שקרים-במחסום.jpg
-שקרים-במחסום.jpg (31.53 KiB) געזען 1998 מאל
חוח בין השושנים האט געשריבן:
אוועטאר
יוסף פריעדמאן
שר שבעת אלפים
תגובות: 7403
זיך איינגעשריבן אום: דאנערשטאג אפריל 30, 2015 4:31 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך יוסף פריעדמאן »

אוראייניקל האט געשריבן:
שמואל בארג האט געשריבן:אין די סעריע פון עליגעיטערס:

נתניהו עדכן כי חבר הכנסת משה גפני לקה בהתקף לב ולאחר כמה דקות תיקן: קיבלתי דיווח פייק ניוז, הוא רק קיבל חיסון.

געמיינט סאיז א ווערטל, ס'איז אבער טאקע געשען.
https://drive.google.com/file/d/1tW5eSx ... sp=sharing

געהערט איינער טענה'ט אז ער איז בלויז פארקילט, און איינער האט פאר א גוט יאהר מחליט געווען אז ס'איז כדאי צו ליגן אין שפיטאל אנטשאט אין שטוב.
אין שפיטאל איז נישט געווען בעטן האט מען איהם געלייגט שלאפן אין ICU, אבער בעצם איז נאר פארקילט...
כי לך טוב להודות

. ע . ע . ע . ש . ע . . ש . . ש . ע . ש . ש . ע ולשמחה נאה לזמר . ע . ע
אוועטאר
אוראייניקל
רב הצעיר תשפ"ד
תגובות: 16943
זיך איינגעשריבן אום: דאנערשטאג פעברואר 21, 2019 9:05 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך אוראייניקל »

-מפלגות-שאובחנו.jpg
-מפלגות-שאובחנו.jpg (47.46 KiB) געזען 1796 מאל
חוח בין השושנים האט געשריבן:
אוועטאר
moishy56
שר עשרת אלפים
תגובות: 19657
זיך איינגעשריבן אום: זונטאג נאוועמבער 10, 2013 6:36 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך moishy56 »

מדינת ישראל האט שוין וואקסינירט 26.83 פראצענט
פון אלע אירע בירגער.

vaccines per 100ppl.jpg
vaccines per 100ppl.jpg (161.68 KiB) געזען 1702 מאל
.

טעקסט בלויז די ווארט INFO צו 718-480-0545 און מען ארלעדיגט דיר א פאלעסי #קהלייף
מצליח
שר חמש מאות
תגובות: 818
זיך איינגעשריבן אום: זונטאג נאוועמבער 01, 2020 10:33 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך מצליח »

די גרין קארד וואס מדינת ישראל טיילט פאר די וועלכע האבן זיך שוין וואקסינירט
IMG_20210118_181300_072.jpg
IMG_20210118_181300_072.jpg (130.13 KiB) געזען 1589 מאל
ברטם
שר חמישים
תגובות: 58
זיך איינגעשריבן אום: מיטוואך יוני 12, 2019 12:34 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך ברטם »

ההסכם המלא נחשף: ישראל שותפה פעילה במחקר של פייזר

לאחר הביקורת והטענות להיעדר שקיפות מצד משרד הבריאות לאחר החתימה עם חברת התרופות האמריקנית 'פייזר', חשף היום (ראשון) המשרד את הסכם שיתוף הפעולה עמו, שמסדיר את העברת המידע לחברה. המשרד העלה את ההסכם לאתר האינטרנט שלו, אך יש לציין כי חלקים מההסכם הושחרו.


ההסכם נוגע לאיסוף מידע אפידמיולוגי של "עולם אמיתי", כלומר אינפורמציה שנאגרת מהשטח בעקבות השימוש בחיסון. נכתב בו כי הצדדים מסכימים לשתף פעולה, לחלוק מידע שנוגע למתן החיסון ולשימוש בו ולעקוב אחר יתרונותיו. פייזר מתחייבת שלא להשתמש במידע שתקבל לכל מטרה שאינה שיפור בריאות הציבור או שירותי הבריאות.


על פי ההסכם, חברת פייזר תקבל מידע על אודות מספר הנדבקים בנגיף המתגלה בישראל מדי שבוע, מספר המאושפזים בבתי החולים ובהם מספר החולים במצב קשה וקריטי, ומספר החולים הזקוקים למכונות הנשמה. עוד הועבר מידע כללי אך בלתי מזהה על המתחסנים כמו גילאים ומקום מגורים. כמו כן, הצדדים הסכימו להיפגש על בסיס שבועי בשיחת ועידה בווידאו, כדי לדון בתוצאות המחקר.
אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

ברטם האט געשריבן:ההסכם המלא נחשף: ישראל שותפה פעילה במחקר של פייזר

לאחר הביקורת והטענות להיעדר שקיפות מצד משרד הבריאות לאחר החתימה עם חברת התרופות האמריקנית 'פייזר', חשף היום (ראשון) המשרד את הסכם שיתוף הפעולה עמו, שמסדיר את העברת המידע לחברה. המשרד העלה את ההסכם לאתר האינטרנט שלו, אך יש לציין כי חלקים מההסכם הושחרו.


ההסכם נוגע לאיסוף מידע אפידמיולוגי של "עולם אמיתי", כלומר אינפורמציה שנאגרת מהשטח בעקבות השימוש בחיסון. נכתב בו כי הצדדים מסכימים לשתף פעולה, לחלוק מידע שנוגע למתן החיסון ולשימוש בו ולעקוב אחר יתרונותיו. פייזר מתחייבת שלא להשתמש במידע שתקבל לכל מטרה שאינה שיפור בריאות הציבור או שירותי הבריאות.


על פי ההסכם, חברת פייזר תקבל מידע על אודות מספר הנדבקים בנגיף המתגלה בישראל מדי שבוע, מספר המאושפזים בבתי החולים ובהם מספר החולים במצב קשה וקריטי, ומספר החולים הזקוקים למכונות הנשמה. עוד הועבר מידע כללי אך בלתי מזהה על המתחסנים כמו גילאים ומקום מגורים. כמו כן, הצדדים הסכימו להיפגש על בסיס שבועי בשיחת ועידה בווידאו, כדי לדון בתוצאות המחקר.

אין קורצן
תושבי מדינת ישראל, זענען 'שפני נסיון' פאר פייזער.
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

-יוצאים-עם-הכלב.jpg
-יוצאים-עם-הכלב.jpg (59.92 KiB) געזען 1523 מאל


-למידה-מרחוק.jpg
-למידה-מרחוק.jpg (261.37 KiB) געזען 1523 מאל


-מוטציה-ישראלית.jpg
-מוטציה-ישראלית.jpg (32.38 KiB) געזען 1523 מאל
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

-מוטציה-מהירה.jpg
-מוטציה-מהירה.jpg (463.73 KiB) געזען 1521 מאל


-מוטציות.jpg
-מוטציות.jpg (104.99 KiB) געזען 1521 מאל


-נוגדי-דיכאון.JPG
-נוגדי-דיכאון.JPG (51.02 KiB) געזען 1521 מאל
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

-סגר-ישראלי.jpg
-סגר-ישראלי.jpg (86.02 KiB) געזען 1519 מאל


-פייק-ניוז-1.jpg
-פייק-ניוז-1.jpg (66.66 KiB) געזען 1519 מאל


-קפסולה-למתחסן.jpg
-קפסולה-למתחסן.jpg (167.07 KiB) געזען 1519 מאל
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

-תופעות-לווי-מהחיסון.jpg
-תופעות-לווי-מהחיסון.jpg (84.17 KiB) געזען 1516 מאל


-תופעת-לווי-מסוכנת.jpg
-תופעת-לווי-מסוכנת.jpg (62.5 KiB) געזען 1516 מאל
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
ברוך פריעדמאן
שר שלשת אלפים
תגובות: 3055
זיך איינגעשריבן אום: זונטאג נאוועמבער 29, 2020 12:09 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך ברוך פריעדמאן »

C7062219-5646-4470-B767-2643FD55654E.jpeg
C7062219-5646-4470-B767-2643FD55654E.jpeg (205.65 KiB) געזען 1481 מאל
ברטם
שר חמישים
תגובות: 58
זיך איינגעשריבן אום: מיטוואך יוני 12, 2019 12:34 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך ברטם »

ברטם האט געשריבן:ההסכם המלא נחשף: ישראל שותפה פעילה במחקר של פייזר

לאחר הביקורת והטענות להיעדר שקיפות מצד משרד הבריאות לאחר החתימה עם חברת התרופות האמריקנית 'פייזר', חשף היום (ראשון) המשרד את הסכם שיתוף הפעולה עמו, שמסדיר את העברת המידע לחברה. המשרד העלה את ההסכם לאתר האינטרנט שלו, אך יש לציין כי חלקים מההסכם הושחרו.


ההסכם נוגע לאיסוף מידע אפידמיולוגי של "עולם אמיתי", כלומר אינפורמציה שנאגרת מהשטח בעקבות השימוש בחיסון. נכתב בו כי הצדדים מסכימים לשתף פעולה, לחלוק מידע שנוגע למתן החיסון ולשימוש בו ולעקוב אחר יתרונותיו. פייזר מתחייבת שלא להשתמש במידע שתקבל לכל מטרה שאינה שיפור בריאות הציבור או שירותי הבריאות.


על פי ההסכם, חברת פייזר תקבל מידע על אודות מספר הנדבקים בנגיף המתגלה בישראל מדי שבוע, מספר המאושפזים בבתי החולים ובהם מספר החולים במצב קשה וקריטי, ומספר החולים הזקוקים למכונות הנשמה. עוד הועבר מידע כללי אך בלתי מזהה על המתחסנים כמו גילאים ומקום מגורים. כמו כן, הצדדים הסכימו להיפגש על בסיס שבועי בשיחת ועידה בווידאו, כדי לדון בתוצאות המחקר.


להלן ההסכם בין פייזר למדינת ישראל

REAL-WORLD EPIDEMIOLOGICAL EVIDENCE
COLLABORATION AGREEMENT





This REAL-WORLD EPIDEMIOLOGICAL EVIDENCE COLLABORATION AGREEMENT dated as of January 6, 2021 (this
“Agreement”) by and between the Israeli Ministry of Health, acting on its own behalf and on behalf
of the State of Israel (the “MoH”), and Pfizer Inc., a Delaware corporation (together with its
Affiliates, “PFIZER”) (each, a “Party” and, collectively, the “Parties”).

WHEREAS, PFIZER and BioNTech SE, a company organized and existing under the laws of
Germany are collaborating to develop a vaccine to address the global COVID-19 pandemic; and

WHEREAS, the Parties had previously entered into the confidential Manufacturing and Supply
Agreement dated (the “Manufacturing and Supply Agreement”), under
which MoH agreed to purchase the Product (as defined below) and PFIZER agreed to manufacture and
supply the Product, all in accordance with the terms of the Manufacturing and Supply Agreement, and
subject to certain conditions precedent, including but not limited to certain regulatory approvals
and supply availability; and

WHEREAS, under Section 2.1(f) of the Manufacturing and Supply agreement, the Parties agreed to
cooperate on a reasonable basis to share information and data regarding the distribution,
administration and use of the Product, including to track its benefits; and

WHEREAS, PFIZER has obtained certain conditional approvals for the Product, including under
Regulation 29(a)(9) of the Israeli Pharmacist Regulations (Medical Preparations), 1986, as amended,
and analogous emergency use authorizations in other jurisdictions; and

WHEREAS, the Parties agree that it would be highly beneficial from a public health perspective to
track pandemic data in accordance with vaccination compliance in a Real-World context to evaluate
whether herd immunity protection is observed during the Product vaccination program rollout.

NOW THEREFORE, for and in consideration of the premises and mutual covenants and agreements
contained herein and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereto intending to be legally bound, hereby agree as
follows:

1. DEFINITIONS

The following terms shall have the meanings assigned to them for all purposes of the Agreement.

1.1 “Affiliate” means, with respect to each Party or, if applicable, BioNTech,
any corporation, firm, partnership or other entity or person which directly or indirectly controls
or is controlled by or is under common control with the named Party, including but not limited to
Pfizer US, or, if applicable, BioNTech. For purposes of this definition, “control” (including,
with correlative meaning, the terms “controlled by” and “under common control with”) shall be
presumed to exist if one of the following conditions is met: (a) in the case of corporate
entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares
having the right to vote for the election of directors of such corporate entity or any direct or
indirect parent of such corporate entity, and (b) in the case of non-corporate entities, direct or
indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct
the management and policies of such non-corporate entities.

1.2 “Global Trade Control Laws” means the U.S. Export Administration Regulations; the U.S.
International Traffic in Arms Regulations; the U.S. economic sanctions rules and regulations
implemented under statutory authority and/or the President's Executive Orders and administered by
the U.S.






Department of the Treasury Office of Foreign Assets Control; European Union (E.U.) Council
Regulations on export controls, including Nos.428/2009, 267/2012; other E.U. Council sanctions
regulations, as implemented in E.U. Member States; United Nations sanctions policies; all relevant
regulations and legislative instruments made under any of the above; other relevant economic
sanctions, export and import control laws, and other laws, regulations, legislation, orders and
requirements imposed by a relevant governmental entity.

1.3 “Identifiable Health Information” means health information, as such term is defined in
the Israeli Patient’s Rights Law, which contains details that identify an individual without cross
referring to additional information, or health information which does not contain details that
identify an individual but that may result in the identification of an individual by either using
reasonable means or other information which is available to the general public.

1.4 “Intellectual Property” means on a worldwide basis any and all (a) patents, applications
for patents (including, without limitation, divisions, continuations, continuations-in-part and
reexamination applications) and any renewals, extensions or reissues thereof; (b) trademarks,
service marks, whether or not registered, copyrights and registrations or applications for
registration of copyrights, rights associated with works of authorship, including copyrights, moral
rights and mask-works; (c) designs, algorithms and other industrial property rights; (d) computer
software, including, without limitation, source code, operating systems and specifications,
documentation and other written materials related thereto; (e) trade secret rights; (f) data; (g)
other ideas, inventions (whether or not patentable), methods, research information and know- how;
(h) reagents, kits, chips, microarrays, instrumentation, devices used for genetic tests,
compositions, methods, markers and method to direct treatment; (i) other intellectual and
industrial property rights of every kind and nature, however designated, whether arising by
operation of law, contract, license or otherwise; and (j) registrations, applications, renewals,
extensions, continuations, divisions or reissues thereof now or hereafter in force (including,
without limitation, any rights in any of the foregoing).

1.5 “Pfizer Data” means aggregated information about the Product in other jurisdictions in
the world, which may include scientific, safety and efficacy information collected by PFIZER as may
be useful to serve the Project's objectives which will be provided by PFIZER to the MoH subject to
applicable legal requirements and based on PFIZER’s reasonable determination.

1.6 “Product” means all vaccines manufactured in whole or in part, or supplied, directly or
indirectly, by or on behalf of PFIZER or BioNTech or any of their Affiliates pursuant to the
Manufacturing and Supply Agreement that are intended for the prevention of the human disease
COVID-19 or any other human disease, in each case which is cause by any of the virus SARS-CoV-2
and/or any or all related strains, mutation, modifications or derivatives of the foregoing.

1.7 “Project” means the COVID-19 Real-World epidemiological data analyses conducted by the
Parties involving data collected during the MoH’s vaccination program using the Product, as
described in Section 2 and Exhibit A of this Agreement, including components thereof and
enhancements thereto, developed and implemented by the Parties under the terms of this Agreement.

1.8 “Project Data” means any de-identified data provided by the MoH to PFIZER in the
framework of the Project.

1.9 “Regulatory Requirements” The requirements of all applicable national, regional, and
local laws and regulations and court rulings and consent decrees and all requirements, guidelines,
policies and orders of all governmental bodies or agencies having jurisdiction over each of the
Parties and their respective employees and agents with respect to activities taken under this
Agreement. Regulatory Requirements include, but are not limited to, the following:

a) the Israeli Patient’s Rights Law, 1996, as amended;






b) The Israeli Privacy protection law, 1981, as amended' c) the Israeli Public
Health Ordinance, 1940, as amended;
d) the Israeli Pharmacist Regulations (Medical Preparations), 1986, as amended;

e) The Israeli Freedom of Information law, 1998, as amended;

t) anti-btibety laws including the U.S. Foreign Comipt Practices Act, 1977, as amended;
and

g) Global Trade Control Laws.

1.10 "Restricted Party (ies)" means any individual or entity on any of the following: U.S.
Government Suspension and Debatment List; HHS OIG Excluded Patties List; FDA OIG Debarment List;
and any similat· disqualification lists, licensure restiictions, disciplinaty sanctions, or
enforcement action against scientists, health cat·e providers, or reseat·ch professionals under the
laws of Israel, the U.S. or any other jurisdiction.

1.11 "Results" means : (i) epidemiological rep01ts fi:om Israel generated by MoH;
(ii) analyses, that at·e generated by either Patty, independently or jointly with the other
Patty relating to the Prqject Data; and (iii) any epidemiological rep01ts from outside Israel
related to the Product, provided by Pfizer.

1.12 "Term" As defined in Section 4.1.




2. THE PROJECT

2.1 Objective of the Project.

To measure and analyze epidemiological data arising from the Product rollout, to detetmine
whether herd immunity is achieved after reaching a cettain percentage of vaccination coverage in
Israel.

2.2 Principles of Collaboration.

The Patties agree that the Project is intended to generate and analyze epidemiological and
population-level vaccine effectiveness data, vitally necessaty for public health purposes that
may inf01m vaccine technical recommendations globally. The data generated by the Project is aimed
at helping end the global COVID-19 pandemic for the benefit of all patients inside and outside of
Israel. The Project will be based on the cunent medical literature, and guidelines adopted by
respected medical bodies.

To conduct the Project and measure population level impact of the Product, MoH is relying on
receipt of Product doses, in accordance with the tetms of the Manufactming and Supply Agreement,
as may be amended from time to time, and on the product delivety rate by PFIZER to allow
maintaining vaccination rate sufficient to achieving herd immunity and enough data as soon as
possible, and should be agreed by the two patties. Nothing in this Agreement shall modify
or amend in any way the tetms of the Manufactming and Supply Agreement. In case of a
conflict between the tetms of the Manufactming and Supply Agreement and this Agreement in regat·d
to the · and of the the tetms of the
and will control.







2.3 Collaboration Governance.

During the Term, unless the Parties mutually agree to a different frequency, the Parties shall meet
weekly by video conference/tele conference at a mutually convenient time to review and discuss the
status of the development and implementation of the Project. Project team members shall be
determined by the Parties. Each Party shall be responsible for its own costs associated with any
meetings.

3. FUNDING/CONTRIBUTION OF THE PARTIES

No fimding will be provided under this Agreement. Project Data is collected on a routine basis by
MoH for epidemiological, logistical and oversight pmposes to monitor pandemic and vaccination
status, including data detailed in Exhibit A. To maintain the viability and relevance of the
Project, MoH will use its best effmts to ensure timely repmting to PFIZER in accordance
with Exhibit B. Both Parties



assure use
requirements and ensuring patient safety while ensming timely and accurate collection of
epidemiological data, under applicable regulatmy requirements.

PFIZER will collaborate with the MoH in the Project by providing, subject to PFIZER'S
assessment, qualified PFIZER colleagues and consultants with technical knowledge and subject
matter expertise in infectious disease, respiratmy disease, vaccines, epidemiology, infectious
disease modeling, data analysis and public health, and by providing the MoH with the Pfizer Data,
subject to applicable legal requirements and based on PFIZER's reasonable determination.

MoH will share aggregate Project Data with Pfizer and the Parties will jointly analyze such
Project Data. MoH reserves the right to continue analyzing and repmting Public Health data
collected by the MoH, and infmmation about product safety and efficacy, publicly. MoH and Pfizer
will jointly repmt in submission(s) for publication, to peer-reviewed scientific or medical
jomnals, the results of the Project. PFIZER will provide to MoH the Results of Project analyses
conducted by PFIZER or its consultant.


4. TERM AND TERMINATION

4.1 Term.

This Agreement and the obligations of the Pruties heretmder shall commence upon its execution, and
shall smvive until completion of the Project, tmless sooner terminated pursuant to the provisions
of Section 4.2 (the "Term").

4.2 Events of Termination.

This Agreement shall be terminated upon the first to occur of any of the following events (each, an
"Event of Termination"):

4.2.1 the expiration of the Term;

4.2.2 the written agreement of the Pruties hereto to terminate this Agreement;

4.2.3 if PFIZER or the MoH determines that a Project is scientifically futile;






4.2.4 in the event of a catastrophe, such as severe patient safety issue with the Product
resulting in a recall of the Product, requiring early termination of the Project;

4.2.5 in the event of a material breach of this Agreement, the Party alleging such breach
gives written notice thereof to the other Party and such Party fails to cure the breach within
thirty (30) days of such written notice;

4.2.6 either (i) any law, rule or regulation is amended or promulgated, or any new
interpretation is made or given of any law, rule or regulation or (ii) any legal action, including
any investigation, is commenced by a governmental agency against either of the Parties hereto or
their Affiliates which in the case of either (i) or (ii), (x) can reasonably be expected to have a
material adverse effect on such Party’s ability to fulfill its obligations under this Agreement or
(y) renders illegal or unenforceable material obligations of the other Party under this Agreement;
provided, however, that at least 30 days prior to giving notice of termination, the terminating
Party has notified the other Party of its intention to give such notice of termination and has made
reasonable efforts to work with the other Party to modify this Agreement so as to preserve its
essential purpose while at the same time making the effect of the event specified in clause (i) or
(ii) of this Section 4.2(d) not materially adverse to the terminating Party or any of its
Affiliates;



4.2.7 either Party may terminate this Agreement if the other Party breaches any of the
Representations and Warranties contained in this Agreement.

4.3 Effect of Termination.




Except as set forth in the next sentence, termination of this Agreement pursuant to Section 4.2
shall terminate all obligations and liabilities of the Parties hereunder (or with respect to the
individual Project being terminated, as applicable) except for obligations and liabilities
previously accrued. Sections 5, 6, 7, and 8 shall survive any termination of this Agreement. For
the avoidance of doubt, Pfizer is not obligated to return or destroy Project Data or Results,
including after termination of this Agreement.



5. CONFIDENTIALITY

5.1 “Confidential Information” means, other than Exempt Information (defined below), any and
all information, in whatever form or manner presented, and (a) relates to a Party’s
business/operations or plans thereof, technology, research, finances, or any other confidential or
proprietary information that PFIZER or MoH, may disclose through their employees or consultants
under this Agreement to the other Party; (b) is or contains Identifiable Health Information; (c)
Pfizer Data; or (d) is Project Data or Results, unless such Project Data or Results, in the case of
Project Data or Results prepared or compiled by MoH, is considered public health data. “Exempt
Information” means information that the receiving Party can demonstrate (a) was lawfully in its
possession prior to the time of disclosure; (b) is or becomes public knowledge through no fault,
omission, or other act of the receiving Party; (c) is obtained from a third Party lawfully entitled
to possession of such information and under no obligation of confidentiality to the disclosing
Party; or (d) was independently collected or developed by or for the receiving Party without
violating the terms of this Agreement. MoH is entitled to publicly disclose this Agreement, subject
to reasonable redaction of any Confidential Information, to be agreed upon by the Parties.

5.2 The Parties, and each of its employees, agents, subcontractors, affiliates and other
representatives (“Representatives”), shall not, either during or after the term of this Agreement
disclose any Confidential Information to any third Party without the approval of the disclosing
Party; or (b) use Confidential Information for its own benefit or advantage, other than in the
performance of this Agreement.






Each Party shall safeguard the Confidential Inf01mation of the other Party with the same degree of
care as it holds its own confidential inf01mation of like kind, which shall be no less than a
reasonable degree of care. No Identifiable Health Inf01mation shall be shared between the Parties
and the MoH shall provide the Project Data solely in a form rendered anonymized by MoH in
accordance with the Regulatory Requirements such that the Project Data could not reasonably be
used to re-identify the identity of an individual. If Identifiable Health Information is
inadvertently shared by either Party, it shall be treated as Confidential Information by the
receiving Party, immediately returned to the disclosing Party, and destroyed by the receiving
Party.

5.3 In the event that a Party is required by applicable law, regulation or legal process to
disclose any Confidential Information of the other Party, such receiving Party will: (a) notify the
disclosing Party immediately so that the disclosing Party may seek a protective order or other
appropriate remedy and cooperate with disclosing Party in such efforts at the expense of the
disclosing Party, (b) disclose only that portion of the Confidential Information which its legal
counsel determines it is required to disclose, and (c) exercise all reasonable efforts to obtain
assurance that confidential treatment will be accorded to such Confidential Information.

5.4 Any and all written Confidential Information received by a Par·ty Pursuant to
this Agreement shall be retmned to the disclosing Party along with all copies of the same, or shall
be destroyed, upon the request and at the option of the disclosing Party.

5.5 MoH will keep and safely maintain, at its expense, the Project Data, for a period
determined by Israeli applicable laws and regulations, but no less than fifteen (15) years after
Agreement termination, (the "Retention Period").

6. INDEMNIFICATION; LIMITATION OF DAMAGES AND LIABILITY



7. REPRESENTATIONS AND WARRANTIES

7.1 Each Party covenants, represents and wanants to the other Party that such Party has full
right, power and authority to enter into this Agreement and there is nothing which will prevent it
from performing its obligations tmder the terms and conditions of this Agreement;

7.2 Each Party covenants, represents and wanants that it shall, in its respective
performance of this Agreement and the Project, take all actions necessary and appropriate to assure
that it complies with (a) the terms of this Agreement, including any applicable Project plans and
other attachments hereto, and (b) the Regulatory Requirements. Each Party wanants and tmdertakes
that it has obtained all necessary regulatory approvals and permits required under law to transfer
or receive the Project Data, as applicable, and there is no impediment under any law to execute
this Agreement. MoH has determined that no IRB or privacy board approvals are required for the
Project.





7.3 Each Party covenants that all materials, work product and documentation created pursuant
to this Agreement shall not infringe upon any patent, copyright or other intellectual property
rights of any third party.

7.4 Each Party covenants, represents and warrants to the other Party that such Party is not
debarred by any applicable authority, including under subsections 306(a) or (b) of the federal
Food, Drug, and Cosmetic Act, as amended, is not on the U.S. Government Suspension and Debarment
List; HHS OIG Excluded Parties List; or any similar disqualification lists, licensure restrictions,
disciplinary sanctions, or enforcement action against scientists, health care providers, or
research professionals under the laws of Israel, the U.S. or any other jurisdiction and it has not
and shall not use in any capacity the services of any person or entity, including any individuals,
agents, employees, subcontractors, customers, healthcare providers, hospitals, pharmacies, clinics
and any other relevant party that is involved, directly or indirectly, in the activities under this
Agreement, that has been debarred by any such applicable authority with respect to this Agreement.
Such Party shall immediately notify the other Parties in the event that it, its subcontractors or
any of its or their employees becomes debarred or excluded during the Term of this Agreement. Such
Party acknowledges that such debarment shall be grounds for termination of this Agreement by the
other Parties for cause.

7.5 Each Party represents and warrants that the services performed under this Agreement do
not and will not involve the counseling or promotion of a business arrangement or other activity
that violates applicable law. Each Party further represents and warrants that it has not and will
not in the future directly or indirectly offer or pay, or authorize the offer or payment, of any
money or anything of value in an effort to influence any government official or any other person in
order for Pfizer to improperly obtain or retain business or to gain an improper business advantage,
and, has not accepted, and will not accept in the future, such a payment. Each party further
represents and warrants that MOH has been provided with a copy of Pfizer’s International
Anti-Bribery and Anti-Corruption Principles (attached hereto as Exhibit C) and will communicate
such principles to all persons acting on its behalf in connection with the Project, including
agents or subcontractors. For the avoidance of doubt, nothing in this Agreement shall be construed
to (a) obligate MoH to grant regulatory approval, promote, prescribe, purchase, order or recommend,
or arrange for the promotion, prescription, purchase, order or recommendation of any products
manufactured and/or marketed by PFIZER, or (b) obligate MoH to place any products manufactured
and/or marketed by PFIZER on MoH’s formularies (e.g., formularies MoH operates or maintains on
behalf of itself) or third parties (such as sick funds) formularies.

7.6 Each Party represents and warrants the services and any transfers of value provided by
the respective Party, are in no way based upon the value or volume of purchases or business between
the Parties.

7.7 Compliance with Global Trade Controls: The activities covered by this Agreement may be
subject to Global Trade Control Laws. Parties will perform their respective obligations under this
Agreement in full compliance with all applicable Global Trade Control Laws.

7.7.1 Each Party represents and warrants that such party and its respective owners, directors,
and officers are neither a Restricted Party, nor owned or controlled by a Restricted Party. With
respect to the activities performed under this Agreement, each Party confirms that Affiliates,
agents, employees, or subcontractors directly or indirectly involved in the activities contemplated
under this Agreement are not Restricted Parties and that no such Restricted Parties will be engaged
in any activities contemplated under this Agreement or delegated any activities contemplated under
this Agreement. In the event that any of these representations change during the Term of this
Agreement, the Party connected with such a person or entity will immediately inform the other Party
and suspend all related activities and payments under this Agreement until the Parties agree to
move forward.






Notwithstanding any cure periods set fo1th herein, the Parties acknowledge that designation as a
Restricted Pa1ty shall be grotmds for immediate te1mination of this Agreement, in whole or in
relevant pa1t, by the other Party, for cause, with no cure pe1iod.

7.7.2 Parties must include this and all Global Trade Contr·ol Laws provisions above, as well as
related defmitions, in any contract or agreement necessa1y to pe1fo1m , or related to the
performance of the discount anangement under this Agreement.

7.8 PFIZER shall not use the Project Data for any pUipose and in any manner which does not
se1ve to improve healthcare, public health, or is disc1iminato1y in respect of insurance or
employment or has othe1wise an inappropriate social pUipose, and (ii) pe1fo1m or enable to perfo1m
in any way, any activity that may result in exposing the identity or identifying data of
individual patients, in relation to the Project Data, including de-anonymizing or (re)identifying
the Project Data in any way.

7.9 The MoH wanants, represents and covenants that it has obtained all necessary regulato1y
approvals and pe1mits required under law to transfer and grant the license to the Project Data.



8. OWNERSHIP

8.1 Each Party owns its respective Intellectual Prope1ty created or developed
outside this collaboration and prior to the date of this Agreement and all modifications,
improvements or changes in or to such pre-existing Intellectual Property (the foregoing being
refened to as a Party's "Intellectual Property"). For the avoidance of doubt, the Project Data
(but not Pfizer Data) is owned by the MoH or the respective health organization and its tr·ansfer
shall not affect the rights therein, other than the licenses granted under this Agreement.


8.3 As between PFIZER and MoH, PFIZER shall own all1ight, title and interest in and to the
Product, including any Project Intellectual Prope1ty included or or
useful the 1Jt·", r1"''t
· health data collected the MoH





8.4 PFIZER shall have the right to use the Project Data for resear·ch and development
purposes, for submission to the competent authorities, scientific, publication (subject to the
provisions of Section 9) and other legitimate business pUiposes.

9. PUBLICATIONS AND PUBLICITY

9.1 Publications.

9.1.1 PFIZER and MoH will jointly prepare and publish the Results in submission(s) for
publication, to peer-reviewed scientific or medical joUinals. Nothing in this Agreement shall
prevent the MoH from continuing to disseminate Project Data or other data collected by the MoH,
other than Results of the Project objective






specified in Section 2.1, to the public on a regular basis or as required for public health reasons
and according to Israeli laws, or prevent MoH from possessing and analyzing such data, independent
of this agreement and making publications thereof. Nothing in this Agreement shall prevent PFIZER
from making publications using publicly available data. All publications involving the Project,
will acknowledge the role of MoH and Pfizer in the Project.

Without derogating from the generality of the above, to the extent that PFIZER and MoH cannot agree
on a joint publication within a reasonable time, or to the extent that PFIZER or the MoH wishes to
make further publications of data and results from this Agreement other than a joint publication,
each Party will provide to the other Party with a copy of the publication days
prior to the date of submission for publication or of public disclosure to review such material.
During its review period, the other Party may provide input, make factual corrections, and request
the deletion of any reference to the other Party’s Confidential Information from the proposed
disclosure or publication. All disclosures and publications must expressly acknowledge the other
Party, unless such Party objects to such acknowledgment. To the extent the Parties cannot resolve
disputes regarding publications they shall escalate such matters to a good faith discussion
between PFIZER’s and Sharon
Alroy-Preis, MD, MPH, MBA.

9.2 Publicity.

9.2.1 The Parties will issue a press release or public announcement, either joint or solo
(as agreed), about this Agreement, including, information regarding the Project, it's terms and
time after the Effective Date; once content of such an announcement is mutually agreed upon. All
other public announcements (e.g., press releases) about this Agreement shall be mutually agreed
upon and issued at a time mutually agreed by the Parties, except to the extent disclosures are
required by law or necessary to respond to requests of state or federal regulators. Timely written
notice shall be provided to the other Party if a Party is required to make such disclosures.
During the course of this Agreement, if either Party desires to make a public announcement about
this Agreement or the program, such Party shall give reasonable prior advance notice, but in no
event less than days notice, of the proposed text to the other Party for its
prior review and approval.



9.2.2 Except as authorized in this Section, neither Party shall use the corporate or
product name or logo of the other Party in any presentation, including publications, news releases,
promotional materials, advertisement, or other public announcement, whether written or oral,
without the prior written approval of the other Party.

10. GENERAL



10.1 Relationship of the Parties. PFIZER and MoH acknowledge and agree that nothing herein
contained is intended to constitute them as employer/employee, joint ventures or partners, it being
their intention that each Party shall have an independent relationship with the other Party.
PFIZER and MoH acknowledge and agree that the personnel employed by each Party in connection with
any work to be performed pursuant to this Agreement shall remain at all times employees or hired
consultants of such Party, and such Party shall remain solely liable for all aspects of the
employment of such persons including,




recmitment, tennination, training, promotion, compensation, benefits, payroll taxes, severance
pay, and all other deductions or payments to be made by employers for or on behalf of employees.

10.2 Compliance with Laws. MoHand PFIZER shall, in their respective petfotmance of this
Agreement, take all actions necessaty and appropriate to assure that they comply with all
Regulatmy Requirements.

10.3 Hierarchy of Tetms. The tetms and conditions of this Agreement shall apply to any and
all Exhibits or other attachments to this Agreement executed by the Patties that reference this
Agreement. In the event that there are any conflicts between the tetms of this Agreement and the
tetms of any such Exhibits or other attachments to this Agreement, the provisions of this
Agreement shall control. The tetms of this Agreement and the applicable Exhibits and other
attachments, to this Agreement shall be controlling over any tetms of any sales acknowledgement,
invoice or other such documents issued by either Patty.

10.4 Non-Exclusivity. Nothing in this Agreement shall be intetpreted to impose any obligation
of exclusivity of either Party; and either Patty shall be free to work with other third Patties
subject to the tetms of this Agreement, including, but not limited to phatmaceutical
companies, in development of programs and setvices similat·to those programs and setvices set
forth in this Agreement.

10.5 Assignment. No Patty shall assign any of its tights or any of its duties
under this Agreement, without the ptior wtitten consent of the other Patties hereto. Any such
attempted assignment of rights or delegation of duties without the prior wtitten consent of the
other Parties shall be void and ineffective. Any such assignment, or delegation consented to by a
Patty shall not relieve the other Patty of its responsibilities and liabilities hereunder.




mc,d.Il:tca.uon, "'''""'"'"" or
upon
corttaurred in a writing signed by a duly authorized agent for each respective Patty and
specifically refening
hereto or thereto.

10.7 Notices. Any notice required to be given hereunder shall be in wtiting and shall be
deemed to have been given: (a) when received, if delivered in person, (b) on the third business day
following the mailing thereof, if mailed by certified first class mail, postage prepaid, retum
receipt requested, (c) on the next business day after mailing by ovemight courier setvice , or
(d) on the day sent by electronic mail; provided, however, in the case of electronic mail, the
sender shall follow-up with a telephone call to confnm receipt unless the recipient
acknowledges receipt by retum electronic mail, in any such case to the addresses specified below:

Israeli Malth
Attn:Dr. --
39 Yiimiyahu St. Jemsalem 9101002
Email: @moh.gov.il

PFIZER INC.
Dr.-
Pfizer Vaccmes Medical
235 East 42nd Street
NewYork, NewYork 10017






cc: PFIZER INC.
Attn: General Cotmsel
235 East 42nd Street
NewYork, NewYork 10017

PFIZER or MoH may, by written notice to the others, change the addresses and names given above.

10.8 Binding Effect. This Agreement shall be binding upon and shall inure to the benefit
of
PFIZER and MoH their respective successors and pennitted assigns.

10.9 Governing Law All disputes shall be governed by the laws of the State of New York,
USA, without regard to conflict of law principles, except that any dispute regarding the
arbitrability or the scope and application of this Section shall be governed by the Federal
Arbitration Act of the United States.

10.10 Dispute Resolution.







10.11 Expenses. Each of the Patties hereto shall beat· all expenses incuned by it in
connection with the negotiation and preparation of this Agreement and the consummation of the
transactions contemplated hereby and prepat·ation therefore, including, without limitation,
any taxes incuned in connection with the consummation of the transactions contemplated by this
Agreement.

10.12 Independent Patties. The Patties hereto at·e independent contractors engaged in
the operation of their own respective businesses. No Party is, or is to be considered as, the
agent or employee of the other for any pmpose whatsoever. No Patty has the authority to enter into
contracts or assume any obligations for the other Pat·ty or make any watTanties or
representations on behalf of the other Patty. Nothing in this Agreement shall be constmed to
establish a relationship of co-partners or joint ventures between the Patties.

10.13 Third Patty Beneficiaties. None of the provisions of this Agreement shall be for the
benefit of or enforceable by any third patty, including, without limitation, any creditor of any
other party hereto. No such third party shall obtain any right tmder any provision of this
Agreement or shall by reason of any such provision make any claim in respect of any debt, liability
or obligation (or otherwise) against any Patty hereto.

10.14 Counteroatts. This Agreement may be signed in any munber of counterpatts, each of which
for all pUiposes shall be deemed an original, but all of which together shall constitute one and
the same document.

10.15 Severability. Should any part, term or condition hereof be declared illegal or
unenforceable, the validity of the remaining portions or provisions of this Agreement shall not be
affected thereby and the illegal or unenforceable portions of the Agreement shall be enforceable to
the fullest extent allowed by law, while leaving the remaining portions of this Agreement intact.

10.16 Headings. The headings of the Sections of this Agreement are inserted as a matter of
convenience and for reference pUiposes only, are of no binding effect, and in no respect defme,
limit or describe the scope of this Agreement or the intent of any Section.

10.17 Electronic Delivery and Storage. Delivery of a signed Agreement by reliable electronic
means, including facsimile or email (with receipt electronically confumed), shall be an effective
method of delivery of the executed Agreement. This Agreement may be stored by electronic means
and either an original or an electronically stored copy of this Agreement can be used for all
pUiposes, including in any proceeding to enforce the lights or obligations of the Patties to this
Agreement.

10.18 English Language. This Agreement shall be written and executed in, and all other
communications under or in connection with this Agreement shall be in, the English language.
Any translation into any other language shall not be an official version thereof, and in the event
of any conflict in interpretation between the English version and such translation, the English
version shall control.

10.19 FUither Documents. Each Pat·ty hereto agrees to execute such further documents and take
such further steps as may be reasonably necessaty or desirable to effectuate the pUiposes of this
Agreement.






[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]






IN WI1NESS WHEREOF, each of the Patties hereto has caused this Agreement to be duly executed in
its name and on its behalf, all on the date first above written.



ISRAELI MINISTRY OF HEALTH




By:-=----=----=---=,..,-----=----=--=-=----:-,--::-::-
Name: Prof. Chezy Levy, M.D., M.H.A.
Title: Director General


PFIZER INC.




By:

Pfizer Vaccines






Exhibit A

MoH and PFIZER will collaborate on analyses of the data points listed in this Exhibit A. MoH will
provide PFIZER with the data specified in Exhibit B.



Endpoints (beginning and ending dates to be mutually agreed by the Parties)
• Confirmed COVID-19 cases/week
• Confirmed COVID-19 hospitalizations/week
• Confirmed COVID-19 severe/ critical cases /week
• Confirmed COVID-19 ventilator use/week
• Confirmed COVID-19 deaths/week
• Symptomatic cases/week
• Weekly numbers of vaccinees, as total and by age and other demographic subgroups.
• Number of cases per week by age groups, and other demographic factors.
• Additional subgroup analyses and vaccine effectiveness analyses, as agreed by the Parties



Additional potential analyses:
• Direct medical costs averted based on modeled impact of national vaccination program on
outpatient visits, hospitalizations, ICU admissions, etc.






Exhibit B

DATA TRANSFER REQUIREMENTS

MoH will transmit to PFIZER in electronic form aggregate pandemic data as described in this
Exhibit. MoH will use a mutually agreeable electronic transmission method that protects the
security and integrity of the data.

1. STATUS REPORTS

MoH will provide to PFIZER weekly data transfers that include the following information:

1.1 Epidemiological Data

Each data transfer will include, at a minimum, current counts of the following:

• Confirmed COVID-19 cases/week
• Confirmed COVID-19 hospitalizations/week
• Confirmed COVID-19 severe/ critical cases /week
• Confirmed COVID-19 ventilator use/week
• Confirmed COVID-19 deaths/week
• Symptomatic cases/week
• Weekly numbers of vaccinees, as total and by age and other demographic subgroups.
• Number of cases per week by age groups, and other demographic factors.

2. ANCILLARY DOCUMENTS

Both parties will provide to each other as needed the following Ancillary Documents:

2.1 If relevant an electronic “Data Dictionary” consisting of all data variables used,
annotated with variable names and corresponding datasets;

2.2 documentation of statistical programming algorithms used to create the analysis datasets,
methodologies used to convert source data into output (derived) data; and relevant statistical
analysis assumptions or plans; if needed to understand the datasets (e.g., Statistical Analysis
Plan, List of Tables, programming plan);

2.3 any other documentation as may reasonably be requested by either party and mutually
agreed upon by both parties.



2.4 Transfer Schedule.




MoH will transfer aggregate epidemiological data to PFIZER: (i) weekly; (ii) at the end of 1 year
for any residual data both parties mutually agreed upon and other frequency mutually agreed upon.
MoH will work with PFIZER if changes are needed in the data formatting or transmission process to
ensure data quality and usability. Analysis of the data associated with the vaccination project
will be independently or jointly performed by MOH and Pfizer and shared with the other Party. Any
analysis/results Pfizer may perform will be shared with the MOH to discuss and finalize jointly.




Exhibit C

PFIZER’S INTERNATIONAL ANTI-BRIBERY AND ANTI-CORRUPTION PRINCIPLES


1. Pfizer’s Policy

Pfizer has a long-standing policy forbidding bribery and corruption in the conduct of our business
in the United States or abroad. Pfizer is committed to performing business with integrity, and
acting ethically and legally in accordance with all applicable laws and regulations. Pfizer
expects the same commitment from the collaborators, consultants, agents, representatives or other
companies and individuals acting on Pfizer’s behalf (“Business Associates”), as well as those
acting on behalf of Business Associates (e.g., Subcontractors), in connection with work for Pfizer.

2. Bribery of Government Officials

Most countries have laws that forbid making, offering or promising any payment or anything of value
(directly or indirectly) to a Government Official when the payment is intended to influence an
official act or decision to award or retain business. “Government Official” will be interpreted
broadly and means: (a) any elected or appointed Government official (e.g., a legislator or a member
of a Government ministry); (b) any employee or individual acting for or on behalf of a Government
Official, agency or enterprise performing a governmental function, or owned or controlled by, a
Government (e.g., a health care professional employed by a Government hospital or researcher
employed by a Government university); (c) any political party officer, candidate for public office,
officer, or employee or individual acting for or on behalf of a political party or candidate for
public office; (d) any employee or individual acting for or on behalf of a public international
organization; (e) any member of a royal family or member of the military; and (f) any individual
otherwise categorized as a Government Official under law. “Government” means all levels and
subdivisions of Governments (i.e., local, regional or national and administrative, legislative or
executive). Because the definition of Government Official is so broad, it is likely that Business
Associates will interact with a Government Official in the ordinary course of their business on
behalf of Pfizer. For example, doctors employed by Government-owned hospitals are considered
Government Officials.

3. The FCPA

The U.S. Foreign Corrupt Practices Act (the “FCPA”) prohibits making, promising or authorizing a
payment or providing anything of value to a non-U.S. Government Official to improperly or corruptly
influence that official to perform any governmental act or make a decision to assist a company in
obtaining or retaining business, or to otherwise gain an improper advantage. The FCPA also
prohibits a company or person from using another company or individual to engage in any such
activities. As a U.S. company, Pfizer must comply with the FCPA and could be held liable as a
result of acts committed anywhere in the world by a Business Associate.

4. Anti-Bribery and Anti-Corruption Principles Governing Interactions with Governments and
Government Officials

Business Associates must communicate and abide by the following principles with regard to their
interactions with Governments and Government Officials:

4.1 Business Associates, and those acting on their behalf in connection with work for
Pfizer, may not directly or indirectly make, promise or authorize the making of a corrupt payment
or provide anything of value to any Government Official to induce that Government Official to
perform any






governmental act or make a decision to help Pfizer obtain or retain business. Business Associates,
and those acting on their behalf in connection with work for Pfizer, may never make a payment or
offer any item or benefit to a Government Official, regardless of value, as an improper incentive
for such Government Official to approve, reimburse, prescribe, or purchase a Pfizer product, to
influence the outcome of a clinical trial, or to otherwise benefit Pfizer’s business activities
improperly.

4.2 In conducting their Pfizer-related activities, Business Associates, and those acting on
their behalf in connection with work for Pfizer, must understand and comply with any local laws,
regulations or operating procedures (including requirements of Government entities, such as
Government- owned hospitals or research institutions) that impose limits, restrictions or
disclosure obligations on compensation, financial support, donations or gifts that may be provided
to Government Officials. If a Business Associate is uncertain as to the meaning or applicability
of any identified limits, restrictions or disclosure requirements with respect to interactions with
Government Officials, that Business Associate should consult with his or her primary Pfizer contact
before engaging in such interactions.

4.3 Business Associates, and those acting on their behalf in connection with work for
Pfizer, are not permitted to offer facilitation payments. A “facilitation payment” is a nominal
payment to a Government Official for the purpose of securing or expediting the performance of a
routine, non- discretionary governmental action. Examples of facilitation payments include
payments to expedite the processing of licenses, permits or visas for which all paperwork is in
order. In the event that a Business Associate, or someone acting on their behalf in connection
with work for Pfizer, receives or becomes aware of a request or demand for a facilitation payment
or bribe in connection with work for Pfizer, the Business Associate will report such request or
demand promptly to his or her primary Pfizer contact before taking any further action.

5. Commercial Bribery

Bribery and corruption also can occur in non-Government, business to business relationships. Most
countries have laws that prohibit offering, promising, giving, requesting, receiving, accepting or
agreeing to accept money or anything of value in exchange for an improper business advantage.
Examples of prohibited conduct include, but are not limited to, providing expensive gifts, lavish
hospitality, kickbacks or investment opportunities to induce improperly the purchase of goods or
services. Pfizer colleagues are not permitted to offer, give, solicit or accept bribes, and we
expect our Business Associates, and those acting on their behalf in connection with work for
Pfizer, to abide by the same principles.

6. Anti-Bribery and Anti-Corruption Principles Governing Interactions with Private Parties
and Pfizer Colleagues

Business Associates must communicate and abide by the following principles with regard to their
interactions with private parties and Pfizer colleagues:

6.1 Business Associates, and those acting on their behalf in connection with work for
Pfizer, may not directly or indirectly make, promise or authorize a corrupt payment or provide
anything of value to any person to influence that person to provide an unlawful business advantage
for Pfizer.

6.2 Business Associates, and those acting on their behalf in connection with work for
Pfizer, may not directly or indirectly, solicit, agree to accept or receive a payment or anything
of value as an improper incentive in connection with their business activities performed for
Pfizer.






6.3 Pfizer colleagues are not permitted to receive gifts, services, perks, entertainment or
other items of more than token or nominal monetary value from Business Associates, and those acting
on their behalf in connection with work for Pfizer. Moreover, gifts of nominal value are permitted
only if they are received on an infrequent basis and only at appropriate gift-giving occasions.

7. Reporting Suspected or Actual Violations

7.1 Business Associates, and those acting on their behalf in connection with work for
Pfizer, are expected to raise concerns related to potential violations of these International
Anti-Bribery and Anti-Corruption Business Principles or the law. Such reports can be made to a
Business Associate’s primary point of contact at Pfizer or, if a Business Associate prefers, to
Pfizer’s Compliance Group by e-mail at [email protected] or by phone at
1-212-733-3026.
אוועטאר
moishy56
שר עשרת אלפים
תגובות: 19657
זיך איינגעשריבן אום: זונטאג נאוועמבער 10, 2013 6:36 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך moishy56 »

מדינת ישראל האט אויסגעברייטערט די גרופעס בארעכטיגט פאר וויירוס וואקסינען,
עפענענדיג די וואקסין פאר מענטשען פון 40 יאר אלט

ג' בא

אין סך הכל האבן 2.2 מיליאן איינוואוינער שוין באקומען די וואקסין, אויסמאכענדיג ארום 25 פראצענט פון די באפעלקערונג, אבער די וויירוס טוט זיך ווייטער גאר שטארק פארשפרייטן, אזוי ווייט אז מען האט יעצט צום ערשטן מאל באשטעטיגט מער ווי 10 טויזנט פרישע פעלער אין איין טאג.

Yiddish24
.

טעקסט בלויז די ווארט INFO צו 718-480-0545 און מען ארלעדיגט דיר א פאלעסי #קהלייף
אוועטאר
יוסף פריעדמאן
שר שבעת אלפים
תגובות: 7403
זיך איינגעשריבן אום: דאנערשטאג אפריל 30, 2015 4:31 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך יוסף פריעדמאן »

א טאג אזוי
א טאג אזוי
פינדרוס תורה מגנא ומצלא.JPG
פינדרוס תורה מגנא ומצלא.JPG (51.24 KiB) געזען 1241 מאל
פינדרוס מתנגד לפתיחת מוסדות הלימוד.png
פינדרוס מתנגד לפתיחת מוסדות הלימוד.png (30.2 KiB) געזען 1241 מאל
כי לך טוב להודות

. ע . ע . ע . ש . ע . . ש . . ש . ע . ש . ש . ע ולשמחה נאה לזמר . ע . ע
אוועטאר
סטיטשינער
שר עשרים אלף
תגובות: 22670
זיך איינגעשריבן אום: דאנערשטאג יאנואר 05, 2017 3:49 pm
לאקאציע: 50°18′N 21°4′E

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך סטיטשינער »

לייק.

נישטא נאך אזא שפילער און בלאפער ווי אים, אבער אין כאן מקומו. ער איז א גאון אין וויסן וואס די ציבור (פאר וועם ער האלט יעצט א דרשה) וויל הערן.
שפאנט'ס מיט ווארטונג

די רעוואלוציע איז אין פילן שוואנג

טראגטס עס ארויס פון דא!
אוועטאר
גיבראלטאר
שר חמישים ומאתים
תגובות: 278
זיך איינגעשריבן אום: דינסטאג אקטאבער 16, 2018 8:23 pm
לאקאציע: אין אידישן קווארטל

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך גיבראלטאר »

סאיז שוין דא א שמועה און די נייעס, אז סאיז דא א מעגליכקייט פאר א פערטע סגר
צוליב די אויפשטייג פון די נייע ענגלישע מוטציה, און בערך 2 חדשים ארום
וואס קומט אויס פסח צייט, (סתם א צופאל אדער...) זיי זאגן אז און 2 חדשים ארום וועט אלע וויירוס פעלער זיין פון די ענגלישע מוטציה, און נאך מער פון דעם
אפילו אלע וואס האבן גענומען די (צווייטע) חיסון און וועלן אריינקומען אין (לופטפעלד) לאנד
וועלן דארפען גיין און בידוד, איז "מה הועילו טיפשים בתקנתם"
גם זה יעבור
אוועטאר
מאנדלבאום
שר העשר
תגובות: 40
זיך איינגעשריבן אום: מיטוואך אוגוסט 06, 2014 5:16 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך מאנדלבאום »

שמו האט געשריבן:
ברטם האט געשריבן:ההסכם המלא נחשף: ישראל שותפה פעילה במחקר של פייזר

לאחר הביקורת והטענות להיעדר שקיפות מצד משרד הבריאות לאחר החתימה עם חברת התרופות האמריקנית 'פייזר', חשף היום (ראשון) המשרד את הסכם שיתוף הפעולה עמו, שמסדיר את העברת המידע לחברה. המשרד העלה את ההסכם לאתר האינטרנט שלו, אך יש לציין כי חלקים מההסכם הושחרו.


ההסכם נוגע לאיסוף מידע אפידמיולוגי של "עולם אמיתי", כלומר אינפורמציה שנאגרת מהשטח בעקבות השימוש בחיסון. נכתב בו כי הצדדים מסכימים לשתף פעולה, לחלוק מידע שנוגע למתן החיסון ולשימוש בו ולעקוב אחר יתרונותיו. פייזר מתחייבת שלא להשתמש במידע שתקבל לכל מטרה שאינה שיפור בריאות הציבור או שירותי הבריאות.


על פי ההסכם, חברת פייזר תקבל מידע על אודות מספר הנדבקים בנגיף המתגלה בישראל מדי שבוע, מספר המאושפזים בבתי החולים ובהם מספר החולים במצב קשה וקריטי, ומספר החולים הזקוקים למכונות הנשמה. עוד הועבר מידע כללי אך בלתי מזהה על המתחסנים כמו גילאים ומקום מגורים. כמו כן, הצדדים הסכימו להיפגש על בסיס שבועי בשיחת ועידה בווידאו, כדי לדון בתוצאות המחקר.

אין קורצן
תושבי מדינת ישראל, זענען 'שפני נסיון' פאר פייזער.

שפני נסיון? Fake.

אדער איז נישט געהעריג קלאר וואס מיינט "שפני נסיון".

טרעקן איבער אויפירונג און רעזאלטץ מיינט נישט 'געפרואווט' נאר 'געלערנט' - איבעראל אין דער וועלט גייט דער פראצעדור.

ציונים וכו' וועט מען אנשמייסן פאר פיל אנדערע זאכן.
דומהייט האט אויך א שיעור..

האט מיר איינעט געשיקט א צעטאט פון ס'אויבנדערמאנטע פון די... לינקע גרופס און כלערליי אפאזיציע באוועגונגען וואס 'רודערן' הלמאי - "שפני נסיון"...
אפגעזעהן וואס פיל דארט האלטן שוין נאכן זיך וואקסינירן..

דערמאנט מיר וואס נאטרונא ברענגט 'שטאף' פון די לינקע מידיא וואס 'האלטן' קייגן די מדינה..
ווען ס'וואלט נישט געווען מיינע וואלט איך הילכיג גשטורעמט אין מעכטיג געלעכטער...

אנשטולדיגט פארן פארקריכן עטוואס פון 'ענין', אבער ס'עיקר געמיינט ברענגען א ביישפיל.

צוריק צום ענין ...
אוועטאר
שמו
שר ארבעת האלפים
תגובות: 4953
זיך איינגעשריבן אום: מאנטאג אקטאבער 31, 2011 12:38 pm

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך שמו »

מאנדלבאום האט געשריבן:שפני נסיון? Fake.

אדער איז נישט געהעריג קלאר וואס מיינט "שפני נסיון".

טרעקן איבער אויפירונג און רעזאלטץ מיינט נישט 'געפרואווט' נאר 'געלערנט' - איבעראל אין דער וועלט גייט דער פראצעדור.

ציונים וכו' וועט מען אנשמייסן פאר פיל אנדערע זאכן.
דומהייט האט אויך א שיעור..

האט מיר איינעט געשיקט א צעטאט פון ס'אויבנדערמאנטע פון די... לינקע גרופס און כלערליי אפאזיציע באוועגונגען וואס 'רודערן' הלמאי - "שפני נסיון"...
אפגעזעהן וואס פיל דארט האלטן שוין נאכן זיך וואקסינירן..

דערמאנט מיר וואס נאטרונא ברענגט 'שטאף' פון די לינקע מידיא וואס 'האלטן' קייגן די מדינה..
ווען ס'וואלט נישט געווען מיינע וואלט איך הילכיג גשטורעמט אין מעכטיג געלעכטער...

אנשטולדיגט פארן פארקריכן עטוואס פון 'ענין', אבער ס'עיקר געמיינט ברענגען א ביישפיל.

צוריק צום ענין ...

שוין זעה איך האסט נישט פארשטאנען

זיך לערנען איז אלעמאל ריכטיג, אבער זיין די ערשטע, אויף וועמען מען גייט זיך לערנען

זיין די ערשטע צו מנדב זיין 9 מיליון בירגער צו זיין שפני נסיון, דאס איז א פשע בל יכופר

(איך רעד שוין נישט פון דעם, וואס פאר די נייע מוטציה העלפט דאס נישט לשיטתם, ומה הועילו, אבער שוין).
כשמ"ו כן הוא

סיין זיך אויף מיט די לינק צו Webull stocks platform, און איך און די וועלן פארדינען free stocks נאכן deposit $100 די ערשטע 30 טעג פון אויפסיינען https://act.webull.com/nt/1tSOfvYQhs4K/

גם אני נקי עם נטפרי
אוועטאר
moishy56
שר עשרת אלפים
תגובות: 19657
זיך איינגעשריבן אום: זונטאג נאוועמבער 10, 2013 6:36 am

Re: קורונהוויירוס אין א״י

  • ציטיר
  • צו לייגן א דאנק דארפט איר זיין אריינגעלאגט

תגובה דורך moishy56 »

.
אטעטשמענטס
נתוני קורונה בחסדי עמרם.jpg
נתוני קורונה בחסדי עמרם.jpg (121.95 KiB) געזען 909 מאל
.

טעקסט בלויז די ווארט INFO צו 718-480-0545 און מען ארלעדיגט דיר א פאלעסי #קהלייף
שרייב תגובה

צוריק צו “קאראנא וויירוס”